Regulatory News
Wednesday, July 20, 2016
BRIEF-Xoma wins EU "orphan drug" status for hyperinsulinism drug
* Xoma 358 is in phase 2 development for chi with clinical
sites in united states and european union (eu) actively
enrolling patients
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment